Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evorpacept + Azacitidine in Higher Risk MDS
NCT04417517Phase 1Terminated
- Sponsor
- ALX Oncology
- Start
- Oct 2020
- Primary completion
- Jan 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of evorpacept in myelodysplastic syndrome (MDS) (2 arms), sponsored by ALX Oncology. Primary endpoints: Dose Limiting Toxicities at 28 days, Recommended Phase 2 Dose at 2 years and 1 more. Started Oct 2020; status: terminated.
02
Drugs
evorpacept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04417517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04417517.